オプションチェーンは、Compassの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Compassの市場センチメントを評価します。.

Compass (NYSE:COMP) 株価情報, オプションチェーン

Compass

Compass Inc provides an end-to-end platform that empowers residential real estate agents to deliver exceptional service to seller and buyer clients. The platform includes an integrated suite of cloud-based software for customer relationship management, marketing, client service and other critical functionality, all custom-built for the real estate industry and enabling core brokerage services. Business operations are conducted in the United States and earn revenue domestically.

Compass Inc

Compound - United States Dollar

COMPASS EMP FDS TR DEVELOPED 500 ENHANCED VOLATILITY WEIGHTED INDEX ETF

COMPAGNIE FNCE RCH UN/ADR by Compagnie Financiere Richemont AG

Compagnie Financiere Richemont SA

CIE FINANCIERE RICHMN NEW by Compagnie Financiere Richemont AG

Compagnie Financiere Richemont SA Warrants - Class A Richemont (29/11/2023)

CIE FINANCIERE TRADITION by Cie Financiere Tradition Lausanne ACT

Compagnie Financiere Tradition SA

COMPAGNIE DE ST GABAN ORD by Compagnie de Saint-Gobain

Compagnie de Saint-Gobain SA

COMPAGNIE ST GBN UNSP/ADR by Compagnie de Saint-Gobain

COMPAGNIE DE L ODET by COMPAGNIE DE L ODET

Compagnie de l`Odet

COMPAL ELECTRONICS GDR by Compal Electronics Inc.

Compal Electronics Inc

COMPAL ELECTR S/ADR 144A by Compal Electronics Inc.

COMPANHIA BRSLRA DST ADR by Companhia Brasileira de Distribuicao

Companhia Brasileira De Distribuicao

COMPANHIA BRASRA U/ADR by COMPANHIA BRASILEIRA DE ALUMINIO

Companhia Brasileira de Aluminio SA

Companhia Brasileira de Distribuicao ADR (Sponsored) Repstg Ord

Companhia de saneamento Basico Do Estado De Sao Paulo - Sabesp American Depositary Shares (Each repstg 250 Common Shares)

Companhia De Saneamento Basico Do Estado De Sao Paulo

Companhia Siderurgica Nacional S.A. Common Stock

Companhia Siderurgica Nacional

Compania De Minas Buenaventura SAA

Compania de Transporte de Energia Electrica en Alta Tension Transener SA

Compass Digital Acquisition Corp

COMPASS DIGITAL ACQ A by Compass Digital Acquisition Corp.

Compass Digital Acquisition Corp Units (1 Ord Share Class A & 1/3 War)

Compass Digital Acquisition Corp Warrants (29/09/2026)

Compass Diversified Holdings 7.875% Series C Cumulative Preferred Shares

Compass Diversified Holdings

Compass Diversified Holdings 7.875% Series B Fixed-to-Floating Rate Cumulative Preferred Shares representing beneficial interests in Compass Diversified Holdings

Compass Diversified Holdings 7.250% Series A Preferred Shares representing beneficial interest in Compass Diversified Holdings

D/B/A Compass Diversified Holdings Shares of Beneficial Interest

Compass Gold Corp

COMPASS GROUP PLC ORD NEW by Compass Group Plc

Compass Group PLC

COMPASS GROUP SP/ADR by Compass Group Plc

Compass Minerals International Inc

COMPASS Pathways Plc - American Depository Shares

Compass Pathways PLC

Compass Therapeutics, Inc. - Common Stock

Compass Therapeutics Inc

COMPLETE FINCL SLTNS INC by Complete Financial Solutions, Inc.

Complete Financial Solutions Inc

Complete Solaria Inc

COMPLIANCE ENERGY CORP by Compliance Energy Corp.

Compliance Energy Corp

CompoSecure Inc

CompoSecure, Inc. - Class A Common Stock Ex-distribution When-Issued

COMPREHENSIVE HEALTHCARE by COMPREHENSIVE HEALTHCARE SYS INC.

Comprehensive Healthcare Systems Inc

CompuGroup Medical SE & Co KgaA

COMPUGROUP MED SE&CO ADR by CompuGroup Medical SE & Co. KGaA

CompuMed Inc

Compugen Ltd

COMPUTER & TECHS HLDGS by Computer & Technologies Holdings Ltd.

Computer And Technologies Holdings Ltd

COMPUTER ENGNR&CONSLTNG by Computer Engineering & Consulting Ltd

Computer Engineering & Consulting Ltd

COMPUTER MODELLING GRP by Computer Modelling Group Ltd.

Computer Modelling Group Ltd

Computer Task Group Inc

COMPUTERSHARE LTD ADR by Computershare Ltd.

Computershare Ltd

COMPUTERSHARE LTD AUD by Computershare Ltd.

Compx International Inc

Barclays analyst John Coffey maintains Shift4 Payments (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOUR#NYSE">FOUR</a>) with a Overweight and lowers the price target from $120 to $117.

News

Price Target

Analyst Ratings

FOUR

Barclays Maintains Overweight on Shift4 Payments, Lowers Price Target to $117

WRAP

Wrap Technologies Has Completed The Acquisition Of W1 Global; Terms Not Disclosed

On Monday, Glaukos Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>) received the &#8220;Day 74&#8221; notification from the U.S. Food and Drug Administration (FDA) acknowledging the previously submitted New Drug Application (NDA) for Epioxa (Epi-on), its next-gen corneal cross-linking iLink therapy for keratoconus, a sight-threatening corneal disease, is sufficiently complete to <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43908675/glaukos-announces-fda-acceptance-of-nda-submission-for-epioxa" rel="noreferrer noopener">permit a substantive review</a>.
The Prescription Drug User Fee Act goal date for the completion of the FDA&#8217;s review of the Epioxa NDA is set for Oct. 20, 2025.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/02/43883818/glaukos-delivers-mixed-q4-results-analyst-sees-growing-investor-interest-during-transition" rel="noreferrer noopener">Glaukos Delivers Mixed Q4 Results, Analyst Sees Growing Investor Interest During Transition</a>
&#8220;The acceptance of the Epioxa NDA represents another important step in being able to provide keratoconus patients and the ophthalmic community with the first FDA-approved, non-invasive corneal cross-linking drug therapy that does not require removal of the corneal epithelium, the outermost layer of the front of the eye,&#8221; said Glaukos CEO Thomas Burns.
The NDA submission includes data from two Phase 3 pivotal Epioxa trials, which achieved the pre-specified primary efficacy endpoints and demonstrated favorable tolerability and safety profiles.
Glaukos&#8217; corneal cross-linking iLink therapies use proprietary, bio-activated drug formulations designed to strengthen corneal tissue and halt the progression of keratoconus.
Glaukos&#8217; first-generation iLink therapy, known as Photrexa, or&nbsp;Epi-off, is the first and only FDA-approved therapy that has been shown to slow or halt disease progression.
Epioxa utilizes a proprietary, novel drug formulation designed to penetrate the epithelial layer of the cornea, a stronger UV-A irradiation protocol, and supplemental oxygen to enhance cross-linking.
Price Action: GKOS stock is up 25% at $157.36&nbsp;during the premarket session on last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43890152/insulets-strong-q4-highlights-surging-omnipod-demand-and-growth-potential-analyst-sees-continued-growth-in-2025" target="_blank" rel="noreferrer noopener">Insulet&#8217;s Strong Q4 Highlights Surging Omnipod Demand And Growth Potential: Analyst</a></li>
</ul>
Image: Shutterstock

Health Care

Movers

Trading Ideas

General

GKOS

FDA Sets Decision Date For Glaukos' Keratoconus Treatment Without The Need Of Surgery

Barclays analyst Ramsey El-Assal maintains Remitly Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RELY#NASDAQ">RELY</a>) with a Overweight and raises the price target from $28 to $29.

RELY

Barclays Maintains Overweight on Remitly Global, Raises Price Target to $29

WIIM

WLKP

Westlake Chemical Partners LP shares are trading higher after the company reported better-than-expected Q4 financial results.

Barclays analyst John Coffey maintains Nu Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NU#NYSE">NU</a>) with a Overweight and lowers the price target from $17 to $15.

Barclays Maintains Overweight on Nu Holdings, Lowers Price Target to $15

Barclays analyst Jiong Shao maintains NetEase (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTES#NASDAQ">NTES</a>) with a Equal-Weight and raises the price target from $82 to $104.

NTES

Barclays Maintains Equal-Weight on NetEase, Raises Price Target to $104

Earnings

ICCH

ICC Holdings FY24 EPS $0.54 Vs $0.96 YoY

Shares of aerospace manufacturer and launch service provider Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) are <a href="https://www.benzinga.com/premarket">trading higher in premarket</a> on Monday.
Rocket Lab National Security LLC, a wholly owned subsidiary of Rocket Lab USA, has reached a key milestone with the successful conclusion of the Critical Design Review (CDR) for the <a href="https://www.benzinga.com/pressreleases/25/02/b43910080/rocket-lab-clears-critical-design-review-for-space-force-victus-haze-mission">U.S. Space Force's Space Systems Command </a>(SSC) mission, VICTUS HAZE. 
The VICTUS HAZE mission, led by Space Safari and in collaboration with the Defense Innovation Unit (DIU), aims to quickly deploy a spacecraft capable of performing rendezvous and proximity operations. 
&#8220;The ability to build a spacecraft, launch it, and operate it all in-house, on a tactically responsive timeline, is incredibly rare, but with our extensive launch heritage and deep vertical integration across space systems, we&#8217;re ideally suited to make this mission a success,&#8221; said president and CEO of Rocket Lab National Security, Brad Clevenger.
Also Read: <a href="https://www.benzinga.com/25/02/43880110/james-bond-franchise-shifts-hands-to-amazon-mgm-studios">James Bond&#8217;s New Era: Amazon MGM Studios Takes Creative Reins of Franchise</a>
&#8220;VICTUS HAZE solidifies Rocket Lab as a trusted and highly capable, end-to-end space company that can enable complex missions to serve the needs of the nation,&#8221; Clevenger added.
This spacecraft is specifically designed to address space-based threats, ensuring launch readiness within 24 hours. Rocket Lab&#8217;s Pioneer spacecraft will be launched aboard the company&#8217;s Electron rocket from Launch Complex 1 in Mahia, New Zealand.
Following the successful CDR, the project advances into the production phase. During this phase, the spacecraft and launch vehicle will be integrated and preparations for the ground segment will begin.
The mission aims to showcase the capability to monitor and intercept objects in orbit, strengthening the U.S. Space Force&#8217;s capacity to rapidly address potential space threats.
Price Action: RKLB shares are trading higher by 0.72% at $23.72 in premarket at last check Monday.
Read Next: <a href="https://www.benzinga.com/25/02/43881721/coca-cola-warns-shortage-of-diverse-talent-could-harm-future-success">Coca-Cola Warns Shortage Of Diverse Talent Could Harm Business</a>
Photo: Shutterstock

RKLB

Rocket Lab Achieves Critical Design Review For US Space Force Mission

Barclays analyst Matthew Bouley maintains JELD-WEN Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JELD#NYSE">JELD</a>) with a Equal-Weight and lowers the price target from $9 to $6.

JELD

Barclays Maintains Equal-Weight on JELD-WEN Holding, Lowers Price Target to $6

SaverOne 2014 Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVRE#NASDAQ">SVRE</a>), a transportation safety technology company, has been awarded its <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43910063/saverone-granted-new-patent-in-the-united-states-further-expanding-its-ip-portfolio" rel="noreferrer noopener">13th patent</a> by the United States Patent and Trademark Office (USPTO). Issued on February 18, 2025, under patent number 12,231,899, the patent covers SaverOne&#8217;s system designed to restrict mobile phone use while driving.
This patented technology enhances SaverOne&#8217;s in-vehicle safety system by allowing drivers to access only approved applications, such as navigation or calls, while blocking all others. It achieves this through wireless communication between the vehicle&#8217;s Phone Location Unit and the driver&#8217;s mobile device.
Under U.S. law, the patent term is 20 years from the application&#8217;s effective filing date. With this new patent, SaverOne&#8217;s portfolio includes 23 patents, 13 of which have been granted in various jurisdictions and 10 more pending. 
SaverOne CEO Ori Gilboa emphasized that the latest U.S. patent grant further strengthens the company&#8217;s intellectual property portfolio, highlighting the uniqueness and innovation of its technology. He noted that as mobile phone-related distractions continue to pose a major risk to road safety, SaverOne remains dedicated to developing and protecting advanced solutions to help prevent accidents.
Recently, SaverOne&#8217;s U.S. distributor, Motor Supply, successfully completed a <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43780269/saverone-announces-first-u-s-commercial-agreement-with-fedex-trucking-contractor-mdm-express" rel="noreferrer noopener">pilot with FedEx</a> contractor MDM Express, which led to a full fleet installation. This milestone strengthened SaverOne&#8217;s U.S. expansion and fleet safety impact.
Price Action: SVRE shares are trading higher by 4.62% at $4.31 premarket at the last check Monday.
Image via Shutterstock.

Equities

SVRE

SaverOne Expands IP Portfolio With New US Patent, Stock Gains

UNIT

Uniti Group shares are trading higher after Raymond James upgraded its stock rating from outperform to strong buy.

AREC

American Resources shares are trading higher after the company announced it has agreed to source commodities for refinement by ReElement Technologies.

Barclays analyst Matt Miksic maintains Globus Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>) with a Overweight and raises the price target from $100 to $103.

GMED

Barclays Maintains Overweight on Globus Medical, Raises Price Target to $103

Citizens Capital Markets analyst Patrick Walravens reiterates Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) with a Market Outperform and maintains $450 price target.

Reiteration

Citizens Capital Markets Reiterates Market Outperform on Salesforce, Maintains $450 Price Target

Contracts

VUZI

Vuzix Announces Fulfillment Of Six-Figure Waveguide Order Placed By A Major U.S. Based Defense Contractor For Defense Heads-Up Display

Barclays analyst Terry Ma maintains Fidelity National Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNF#NYSE">FNF</a>) with a Equal-Weight and raises the price target from $61 to $67.

Barclays Maintains Equal-Weight on Fidelity National Finl, Raises Price Target to $67

&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4367689-1&amp;h=202193409&amp;u=https%3A%2F%2Fsabre.com%2F&amp;a=Sabre+Corporation">Sabre Corporation</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SABR#NASDAQ">SABR</a>), a leading global travel technology company, and GOL Linhas Aéreas, one of the leading airlines in Brazil, today announced the extension of their long-standing partnership. The renewed agreement includes the continued use of Sabre's Passenger Service System (PSS) and Global Distribution System (GDS), as well as the adoption of Sabre's Mosaic solutions, such as Ancillary IQ&#x2122; and Dynamic Availability, to support GOL's growth and retailing strategies to improve its revenue performance.
By integrating SabreMosaic modules, GOL aims to enhance its retailing capabilities and offer personalized experiences to travelers. Ancillary IQ&#x2122; will enable GOL to provide personalized and optimized ancillary offers by leveraging AI and real-time data to recommend the right products—such as seat upgrades, baggage, and priority boarding—tailored to each traveler. Meanwhile, Dynamic Availability optimizes pricing in real time by intelligently adjusting seat availability and fare conditions based on market demand and airline strategies. Additionally, GOL is implementing Sabre's Self-Service Reaccommodation solution to empower travelers with tailored rebooking options on their mobile devices, enhancing satisfaction and streamlining operations.

SABR

GOL Linhas Aéreas Strengthens Partnership With Sabre, Leveraging SabreMosaic To Boost Revenue

Barclays analyst Nicholas Campanella maintains Consolidated Edison (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ED#NYSE">ED</a>) with a Underweight and raises the price target from $92 to $95.

Barclays Maintains Underweight on Consolidated Edison, Raises Price Target to $95

LQR House shares are trading higher after the company announced a better-than-expected year-over-year revenue decline for its flagship website despite eliminating advertising on Google and Meta.

Press Releases

EverCommerce Announces Josh McCarter as the Leader of Its EverPro Vertical

Real Estate

Compass, Christie's International Real Estate, @properties, and Ansley Real Estate Agree to Join Forces

Compass to Present at the 27th Annual Needham Growth Conference

Quad-C Management Completes the Sale of @properties to Compass

Compass Raises Fourth Quarter and Full-Year 2024 Outlook Ahead of Investor Conference

Christie' s International Real Estate Expands into Mexico's Yucatan Peninsula    with Leading Brokerage Firm

Compass Launches Compass One: The Industry's First-Ever All-in-One Client Dashboard Connecting Compass Agents to Their Clients In Real Time

Compass to Announce Fourth Quarter and Full-Year 2024 Results on February 18

From Emerging Markets to Heritage Architecture, the Christie's International Real Estate Global Luxury Forecast Reveals Themes Shaping Luxury Real Estate in 2025

Compass, Inc. Reports Fourth Quarter and Full-Year 2024 Results

COMP

EVCM

Altisource Portfolio Solutions S.A. - Common Stock

Altisource Portfolio

KE Holdings Inc American Depositary Shares (each representing three Class A Ordinary Shares)

Comments

Compass

Compass (COMP) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル